NEOVACS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE

Paris,  January 19, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be presenting at the BIO CEO & Investor Conference to be held in New York on February 9-10, 2015.

The 17th Annual BIO CEO & Investor Conference attracts over 750 investors and takes place at the Waldorf Astoria, New York. A select number of biotech CEOs are given the opportunity to introduce their companies, technology and development programs.

Miguel Sieler, CEO of Neovacs, will present on February 9, 2015 at 9:30 am E.T.

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr:
http://www.neovacs.fr

                    
Contacts

NEOVACS
                                            
Nathalie Trépo                                                                                                  
+33 (0)1 53 10 93 00                                       
ntrepo@neovacs.com:
mailto:ntrepo@neovacs.com

Press - Financial Communications- Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35 

stéphanie.tabouis@consultants.publicis.fr:
mailto:stéphanie.tabouis@consultants.publicis.fr                                    

Investor Relations - Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
Raimund.Gabriel@mc-services.eu:
mailto:Raimund.Gabriel@mc-services.eu

Press - U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023                                                                                                                              msollid@theruthgroup.com:
mailto:msollid@theruthgroup.com

Neovacs:
http://hugin.info/160718/R/1888150/668116.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire
HUG#1888150